BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30985497)

  • 21. Immunotherapy of renal cell carcinoma.
    Gouttefangeas C; Stenzl A; Stevanović S; Rammensee HG
    Cancer Immunol Immunother; 2007 Jan; 56(1):117-28. PubMed ID: 16676181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Not Available].
    Vano YA; Simonaggio A; Thibault C; Oudard S
    Bull Cancer; 2018 Dec; 105 Suppl 1():S24-S34. PubMed ID: 30595195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel immunotherapeutic strategies in development for renal cell carcinoma.
    Inman BA; Harrison MR; George DJ
    Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cell-based immunotherapy of renal cell carcinoma.
    Gitlitz BJ; Figlin RA; Pantuck AJ; Belldegrun AS
    Curr Urol Rep; 2001 Feb; 2(1):46-52. PubMed ID: 12084295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination immunotherapy in renal cell carcinoma.
    Drake CG
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):99-100. PubMed ID: 27057808
    [No Abstract]   [Full Text] [Related]  

  • 28. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
    Carlo MI; Voss MH; Motzer RJ
    Nat Rev Urol; 2016 Jul; 13(7):420-31. PubMed ID: 27324121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphocyte therapy of renal cell carcinoma.
    Dillman RO
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for kidney cancer: status quo and the future.
    Bedke J; Stühler V; Stenzl A; Brehmer B
    Curr Opin Urol; 2018 Jan; 28(1):8-14. PubMed ID: 29120911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
    Braun DA; Bakouny Z; Hirsch L; Flippot R; Van Allen EM; Wu CJ; Choueiri TK
    Nat Rev Clin Oncol; 2021 Apr; 18(4):199-214. PubMed ID: 33437048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel treatment strategies in clear-cell metastatic renal cell carcinoma.
    van Spronsen DJ; de Weijer KJ; Mulders PF; De Mulder PH
    Anticancer Drugs; 2005 Aug; 16(7):709-17. PubMed ID: 16027518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of metastatic renal cell cancer.
    Fishman M; Seigne J
    Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy options in metastatic renal cell cancer: where we are and where we are going.
    Passalacqua R; Buti S; Tomasello G; Longarini R; Brighenti M; Dalla Chiesa M
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1459-72. PubMed ID: 17069530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New immunotherapy in the treatment of advanced renal cancer.
    Muto A; Gridelli C
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):233-237. PubMed ID: 31751164
    [No Abstract]   [Full Text] [Related]  

  • 37. Allogeneic stem-cell transplantation in renal-cell carcinoma.
    Hayes-Lattin BM; Maziarz RT; Beer TM
    Curr Oncol Rep; 2001 Sep; 3(5):433-7. PubMed ID: 11489245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
    Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma.
    Mollica V; Santoni M; Di Nunno V; Cimadamore A; Cheng L; Lopez-Beltran A; Battelli N; Montironi R; Massari F
    Curr Drug Targets; 2020; 21(14):1463-1475. PubMed ID: 32160846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.
    Murphy KA; James BR; Guan Y; Torry DS; Wilber A; Griffith TS
    Hum Vaccin Immunother; 2015; 11(7):1612-20. PubMed ID: 25996049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.